Table 1 Patient, tumor, treatment characteristics before and after propensity score matching
From: Role of a multidisciplinary team in administering radiotherapy for esophageal cancer
| Variables | Before matching | After matching | ||||||
|---|---|---|---|---|---|---|---|---|
| All n = 212 | MDT n = 157 | Non-MDT n = 55 | P | All n = 106 | MDT n = 53 | Non-MDT n = 53 | P | |
| Age(y) | 64 (44–89) | 64 (44–89) | 64 (46–88) | 0.52 | 64 (44–89) | 63 (44–89) | 65 (46–88) | 0.56 |
| < 60 | 66 (31.1%) | 44 (28%) | 22 (40%) | 0.26 | 38 (35.8%) | 18 (34%) | 20 (37.7%) | 0.33 |
| 60–75 | 115 (54.2%) | 89 (56.7%) | 26 (47.3%) | 43 (40.6%) | 25 (47.2%) | 18 (34%) | ||
| ≥ 75 | 31 (14.6%) | 24 (15.3%) | 7 (12.7%) | 25 (23.6%) | 10 (18.9%) | 15 (28.3%) | ||
| Sex | ||||||||
| Male | 182 (85.8%) | 137 (87.3%) | 45 (81.8%) | 0.32 | 89 (84%) | 45 (84.9%) | 44 (83%) | 0.79 |
| Female | 30 (14.2%) | 20 (12.7%) | 10 (18.2%) | 17 (16%) | 8 (15.1%) | 9 (17%) | ||
| PS | ||||||||
| 0–1 | 197 (92.9%) | 146 (93%) | 51 (92.7%) | 0.37 | 98 (92.5%) | 49 (92.5%) | 49 (92.5%) | 1 |
| 2–3 | 15 (7.1%) | 11 (7%) | 4 (7.3%) | 8 (7.5%) | 4 (7.5%) | 4 (7.5%) | ||
| Location | ||||||||
| Neck-Upper | 42 (19.8%) | 30 (19.1%) | 12 (21.8%) | 0.33 | 21 (19.8%) | 10 (18.9%) | 11 (20.8%) | 0.81 |
| Middle-Lower | 170 (80.2%) | 127 (80.9%) | 43 (78.2%) | 85 (80.2%) | 43 (81.1%) | 42 (79.2%) | ||
| Histologic type | ||||||||
| SCC | 196 (92.5%) | 145 (92.4%) | 51 (92.7%) | 0.93 | 97 (91.5%) | 48 (90.6%) | 49 (92.5%) | 1 |
| Adeno or others | 16 (7.6%) | 12 (7.6%) | 4 (7.3%) | 9 (8.5%) | 5 (9.4%) | 4 (7.5%) | ||
| Stage | ||||||||
| I-II | 50 (23.6%) | 33 (21.6%) | 16 (29.1%) | 0.52 | 30 (28.3%) | 14 (26.4%) | 16 (30.2%) | 0.77 |
| III | 147 (69.3%) | 112 (71.3%) | 35 (6360%) | 66 (62.3%) | 33 (62.3%) | 33 (62.3%) | ||
| IV | 15 (7.1%) | 11 (7%) | 4 (7.3%) | 10 (9.4%) | 6 (11.3%) | 4 (7.5%) | ||
| Differentiation | ||||||||
| I-II | 67 (31.6%) | 54 (34.4%) | 13 (23.6%) | 0.33 | 27 (25.5%) | 14 (26.4%) | 13 (24.5%) | 0.91 |
| III-IV | 57 (26.9%) | 41 (26.1%) | 16 (29.1%) | 28 (26.4%) | 13 (24.5%) | 15 (28.3%) | ||
| unknown | 88 (41.5%) | 62 (39.5%) | 26 (47.3%) | 51 (48.1%) | 26 (49.1%) | 25 (47.2%) | ||
| Treatment modality | ||||||||
| With operation | 104 (49.1%) | 77 (49%) | 27 (49.1%) | 1 | 50 (47.2%) | 24 (45.3%) | 26 (49.1%) | 0.7 |
| non-operation | 108 (50.9%) | 80 (51%) | 28 (50.9%) | 56 (52.8%) | 29 (54.7%) | 27 (50.9%) | ||
| With chemotherapy | 171 (80.7%) | 133 (84.7%) | 38 (69.1%) | 0.01 | 78 (73.6%) | 40 (75.5%) | 38 (71.7%) | 0.66 |
| non-chemotherapy | 41 (19.3%) | 24 (15.3%) | 17 (30.9%) | 28 (26.4%) | 13 (24.5%) | 15 (28.3%) | ||